A Randomized, Double-Masked, Sham-Controlled Clinical Trial of Intravitreal Faricimab for Chronic Central Serous Chorioretinopathy With or Without Secondary Macular Neovascularization: Study Protocol for a Randomised, Double-Masked Trial

Dysregulation of the Angiopoietin-2 (Ang-2)/Tyrosine kinase with Immunoglobulin-like and EGF-like domains 2 (Tie-2) signaling pathway has been implicated in choroidal vascular instability and RPE dysfunction in Central serous chorioretinopathy (CSCR) and pachychoroid-associated neovascularization.
This study prospectively evaluates the efficacy and safety of faricimab compared to sham in CSCR with and without secondary neovascularization, using standardized anatomical and functional endpoints. The results of this trial may help define the role of dual pathway inhibition in CSCR and inform future treatment strategies for this challenging and vision threatening condition.

Start Date01 Dec 2026

Sponsor / Collaborator

Singapore National Eye Centre Pte Ltd.

NCT07753616

/ Not yet recruitingPhase 4IIT

South Asian Patients With Diabetic Macular Oedema Treated With Faricimab Assessing the Efficacy, Durability, and Safety (SEAFAR Study)

The YOSEMITE and RHINE trials, which studied DMO treated with faricimab, had a majority Caucasian cohort, and the small Asian cohort was East Asian, with no South Asian representation. South Asians have a much higher prevalence of diabetes and its ophthalmic complication of DMO.
The SEAFAR study is designed to address this unmet need by specifically evaluating faricimab in a UK-based South Asian cohort with diabetic macular oedema (DMO), delivered via a pragmatic treat-and-extend regimen, for clinically meaningful visual acuity gains, durable anatomic control of DMO, and an acceptable safety profile at week 88 in South Asian patients, with interim benefits by week 52.

Start Date01 Nov 2026

Sponsor / Collaborator-

NCT07695298

/ RecruitingPhase 4IIT

A Prospective Longitudinal Analysis of Faricimab (Vabysmo 6mg) For Choroidal Neovascularization in Presumed Ocular Histoplasmosis Syndrome [PLANE Study]

This study will evaluate the safety and effects, good or bad of faricimab (Vabysmo®), a drug that is approved by the U.S. Food and Drug Administration (FDA) for other retinal conditions, but its use is considered investigational when used specifically for choroidal neovascularization (CNV) related to presumed ocular histoplasmosis (POHS)

Start Date01 Jul 2026

Sponsor / Collaborator

Cincinnati Eye Institute

[+1]

100 Clinical Results associated with Faricimab

100 Translational Medicine associated with Faricimab

100 Patents (Medical) associated with Faricimab

593

Literatures (Medical) associated with Faricimab

01 Aug 2026·ACTA OPHTHALMOLOGICA

Beyond drug price: A comparison of overall costs of anti‐vascular endothelial growth factor therapy alternatives for neovascular age‐related macular degeneration in Norway

Article

Author: Løkken, Jacopo F. T. ; Moe, Morten Carstens ; Jørstad, Øystein Kalsnes ; Sæther, Erik Magnus

Abstract:

Purpose:

Norwegian guidelines designate off‐label Avastin as the first‐line intravitreal therapy for neovascular age‐related macular degeneration ( nAMD ) because of its well‐documented clinical efficacy and low price. However, this overlooks non‐drug costs, which increase with injection frequency. We evaluated whether newer, longer‐acting agents offer greater long‐term cost‐efficiency by reducing total costs despite higher drug prices in a Norwegian setting.

Methods:

We developed a 2‐year cost‐minimization model that included pharmaceutical, consultation and administrative and patient‐related costs in Norway; the pharmaceutical cost component incorporated the routine practice of splitting vials into prefilled syringes in hospital pharmacies. The model compared four nAMD monotherapies, Avastin, Eylea 2 mg, Eylea 8 mg and Vabysmo, as well as the common practice of switching treatment‐resistant patients from Avastin to Eylea 2 mg. We derived injection frequencies from clinical trials (for monotherapies) or observational data (for switching) and conducted one‐way sensitivity analyses to identify key cost drivers.

Results:

Over 2 years, the switching regimen had the highest per‐patient cost (146 722 NOK), followed by Eylea 2 mg (100 481 NOK), Vabysmo (93 207 NOK), Avastin (86 262 NOK) and Eylea 8 mg (68 738 NOK). Avastin had the lowest drug cost, but its high injection frequency increased non‐drug costs. Sensitivity analyses showed that injection frequency strongly influenced total costs for high‐priced drugs, while patient time had a substantial impact for Avastin.

Conclusion:

In our model, longer‐acting agents reduced injection frequency and decreased overall treatment costs. These findings suggest that adopting longer‐acting monotherapy could improve cost‐efficiency in long‐term nAMD management in Norway.

01 Aug 2026·Ophthalmology and Therapy

Real-Life 1-Year Results and Predictors of Visual Outcome with Intravitreal Faricimab for Treatment of Exudative Neovascular Age-Related Macular Degeneration

Article

Author: Beretta, Federico ; Querques, Giuseppe ; Bandello, Francesco ; Balduzzi, Edoardo ; Scalabrin, Giovanni ; Puligheddu, Stefano ; Sacconi, Riccardo

INTRODUCTION:

The purpose of this study was to report 1-year real-world outcomes of faricimab for the treatment of macular neovascularization secondary to age-related macular degeneration (nAMD). Early predictors of functional outcome were investigated.

METHODS:

This was a retrospective, longitudinal study including 132 eyes with nAMD (27% treatment-naïve, 73% switchers) treated with faricimab following a treat-and-extend protocol. Primary outcomes were best-corrected visual acuity (BCVA) and central macular thickness (CMT) changes at 1-year follow-up. Secondary outcomes included possible early predictors of 1-year functional outcomes. Early predictors were investigated at the baseline and after the loading phase.

RESULTS:

After the loading phase, both BCVA (from 0.40 ± 0.33 to 0.35 ± 0.34 LogMAR) and CMT (from 403 ± 135 to 317 ± 108 um) improved significantly (p = 0.014 and p > 0.001 respectively). At 1 year, only CMT reduced significantly (from 403 ± 135 to 317 ± 114 um, p < 0.001), and 36% of eyes were defined as good visual responders (≥ 5 ETDRS letters gain). Predictors of good response were lower BCVA and absence of type 3 macular neovascularization (MNV) at baseline and lower CMT after loading phase. Approximately 60% of patients achieved ≥ Q12-week dosing. Treatment-naïve patients achieved higher extension rates (82% ≥ Q12). No cases of intraocular inflammation were observed.

CONCLUSIONS:

In our real-world practice, faricimab effectively controls nAMD, offering significant anatomical benefits and visual stability with extended dosing intervals. Approximately 80% of treatment-naïve patients maintained ≥ Q12-week schedules. Early anatomical response, defined by reduction in CMT and absence of exudative signs on structural optical coherence tomography (OCT), emerged as a clinically relevant prognostic factor for 1-year outcomes.

21 Jul 2026·RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES

Community-Level Variation in On-Label Versus Off-Label Anti-VEGF Use and Medicare Part B Spending

Article

Author: Wubben, Thomas J. ; Franco, Jovany J. ; Johnson, Mark W. ; Song, Amy ; Williams, George A. ; Pan, Warren W.

Purpose::

To examine whether community-level sociodemographic characteristics are associated with differences in on-label versus off-label anti-VEGF agent use under Medicare Part B and to estimate differential spending attributable to variation in community-level agent mix.

Methods::

Part B claims data (2013-2023) were analyzed to identify providers billing for on-label (aflibercept, ranibizumab, faricimab, brolucizumab, and biosimilars) or off-label (bevacizumab) anti-VEGF injections. For each provider year, 15-min drive-time service areas were generated and overlaid on U.S. Census tracts enriched with American Community Survey-derived sociodemographic data. Community-level profiles were generated through population-weighted aggregation of tracts within each service area. Multivariable logistic regression estimated adjusted marginal effects (AMEs) of sociodemographic variables on on-label anti-VEGF proportion. Counterfactual simulations estimated Part B spending under alternative community-level agent mix scenarios.

Results::

From 2013-2023, 5,178 providers billed Part B for 34.5 million anti-VEGF injections. Higher on-label use was associated with greater community-level proportions of Medicare-aged (AME per 10-percentage-point [pp] increase: +6.1 pp [95% CI: 3.1-9.0]), Black/African American (+2.4 [1.5-3.3]), and college-educated residents (+3.2 [1.9-4.5]). An inverse association was observed for proportion very low-income residents (-3.1 [-5.3 to -0.8]), while no association was observed for proportion Hispanic/Latino residents (+0.4 [-0.6-1.3]) or population density (AME per doubling: +0.8 [-0.2-1.8]). Equalizing anti-VEGF mix to that of the highest-poverty quartile would have resulted in approximately $4.2 billion lower spending.

Conclusions::

Despite uniform reimbursement, significant community-level differences exist in on-label anti-VEGF use within Medicare Part B. These gradients produce billions of dollars in differential spending and raise questions of access, equity, and value-based care.

355

News (Medical) associated with Faricimab

25 Aug 2026

·www.prnewswire.com

Innovent Announces 2026 Interim Results and Business Updates

Transforming from Regional Leader to Global Premier: A Clear Strategic Path for Growth and Globalization SAN FRANCISCO and SUZHOU, China, Aug. 25, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, announces its 2026 interim results and 2030 strategic vision. Dr. Michael Yu, Founder, Chairman of the Board and CEO of Innovent, stated: "Looking back over the past fifteen years, Innovent has completed two key transformations: from 2016 to 2020, we transformed from an R&D-driven biotech company into a biopharmaceutical company with full-value-chain capabilities spanning R&D, manufacturing, and commercialization; from 2021 to 2025, we progressed from a long-term investment phase into a biopharmaceutical company that achieved revenue over RMB 10 billion and full-scale profitability. 2026 marks Innovent's best strategic window to date, and it is against this backdrop that we have set forth our new strategic goals for 2030. We have both the resolve and the confidence to drive our third critical transformation: evolving from a regional leading biopharmaceutical company into a global premier biopharma with global business operational capabilities. In the first half of 2026, Innovent delivered strong growth in both revenue and profit, further reinforcing our leading position in China's biopharmaceutical industry and highlighting our scarce value in both certainty and growth potential. At the same time, over the past ten months, we have reached multiple strategic collaborations with global multinational pharmaceutical leaders including Takeda, Eli Lilly, and Pfizer, while also partnering with biotechs such as Ollin and Spero to advance the global development of our differentiated pipeline. Our partnered pipeline now spans more than 20 assets, including 5 co-development and co-commercialization ("Co-Co") programs, with an aggregate deal value reaching USD 34 billion, representing more than 30% of the total out-licensing value among Chinese pharmaceutical companies over the same period1. Innovent stands at the most favorable strategic window in its development. We will continue to pursue high-quality growth in revenue and profit, guided by clear strategy and disciplined execution — strengthening and amplifying our 'dual-engine' advantage across oncology and general biomedicine, accelerating our global expansion, and advancing toward our 2030 strategic goals, so as to continue creating long-term value for our shareholders and society." A Visible Growth Path: Scale and Profitability Advancing in Parallel In the first half of 2026, Innovent reached RMB 8.6 billion in total revenue, representing 45% year-over-year growth, while product revenue reached RMB 8.2 billion, up 57% year over year. Building on the RMB 10 billion-plus revenue scale, Innovent maintained strong growth momentum, with its dual-engine strategy of oncology and general biomedicine continuing to deliver. Rapid revenue growth, coupled with continued improvements in operational efficiency, further drove improvements in profitability. IFRS net profit for the first half of the year was approximately RMB 1.3 billion, representing approximately 50% year-over-year growth, while Non-IFRS net profit reached RMB 1.7 billion, up 41% year over year. Innovent has entered a new stage characterized by simultaneous expansion in scale and improvement in earnings quality, setting a new paradigm for high-quality growth among biopharmaceutical companies. As of July 31, 2026, Innovent held RMB 30.2 billion in cash reserves, equivalent to approximately US$4.5 billion. In addition, we continued to generate positive cash flow, providing a strong financial foundation for long-term growth. Vision 2030: From China Leader to Global Premier Biopharma Building on high-quality growth and systematic portfolio development, the Company has underpinned its 2030 development goals. Revenue Scale: By 2030, we target to achieve total revenue of RMB 35–40 billion, largely driven by organic expansion from the existing business and pipeline. Sustainable Profitability: By 2030, we aim to benchmark our profit margin to top-tier pharmaceutical companies, through continued revenue expansion and efficiency improvements. Global Innovation: By 2030, we aim to advance at least five molecules into global MRCT Phase 3 development, achieve product launches in key markets, i.e. U.S. and Europe with international revenue emerging. Globalization: building global infrastructure and business operating capabilities, truly transforming into a global premier biopharmaceutical company. From "Product-led Growth" to "Portfolio-Driven Growth," with Dual Growth Engines Unleashing New Momentum China's Leading Oncology Franchise: Strengthening Core Oncology Leadership While Expanding Strategically into Key Growth Areas In oncology, Innovent has established a strong product portfolio and brand presence across core indications including lung cancer, gastrointestinal cancers and hematological malignancies. Focusing on the next-generation "IO + ADC" innovation strategy, the Company is advancing next-generation assets including IBI363 (PD-1/IL-2α-biased), IBI343 (CLDN18.2 ADC), and IBI3003 (GPRC5D/BCMA/CD3) into late-stage clinical development, establishing long-term growth drivers and competitive advantages across multiple strategic areas. Meanwhile, through its collaboration with Lilly on Verzenio® (abemaciclib) in breast cancer, we have strategically gained an important entry point into this major high-incidence tumor type. This asset lays the foundation for upcoming in-house pipeline programs such as IBI354(HER2 ADC) and IBI3014(PD-L1/TROP2 ADC), and paves the way for a more systematic presence in breast cancer. General Biomedicine Franchise Emerged as a New Growth Engine In general biomedicine, Innovent has established a clear framework across four major chronic disease areas—metabolic, cardiovascular, ophthalmology and autoimmune—and this franchise has become another core pillar of Innovent. SYCUME® (Teprotumumab, IGF-1R antibody), China's first innovative therapy for thyroid eye disease in 70 years; Mazdutide, the world's first and only approved GCG/GLP-1 dual-receptor agonist for obesity and type 2 diabetes; and SINTBILO® (tafolecimab injection), the first China-domestic PCSK9 inhibitor included in the NRDL—all exhibited robust performance. PECONDLE® (picankibart injection, IL-23p19 antibody), the anchor asset in autoimmune diseases, was also approved at the end of 2025. At the same time, our next‑generation metabolic and obesity pipeline – including IBI3032 (once‑daily oral GLP‑1), IBI3042 (once‑weekly oral GLP‑1), IBI3040 (Amylin), IBI3046 (INHBE siRNA) and IBI3030 (monthly PCSK9‑GGG) – provides deep, long‑term growth reserves in global obesity and metabolic disease. In cardiovascular & metabolism, autoimmune and ophthalmology, we are following a "flagship products life cycle management + next‑generation innovation" strategy to build focused product clusters and durable competitive positions in each area. Three Late-Stage Global Assets Unlocking More Than US$60 Billion Total Addressable Market (TAM), and 20+ Partnered Programs Accelerating Global Innovation Innovent is advancing global development of its core assets through multiple collaboration models. Three key assets have entered, or are about to enter, global multi-regional Phase 3 trials, with a combined addressable market estimated at over US$60 billion, and are expected to be major value drivers in the coming years: IBI363 (PD-1/IL-2α-biased, Takeda R&D Code: TAK-928): Next-gen IO cornerstone, potential TAM over US$40 billion for first wave of indications, global co-development with Takeda A global multi-regional Phase 3 study (MarsLight-11) in IO-resistant squamous non-small cell lung cancer (NSCLC) is ongoing, and with expansion into IO-resistant non-squamous NSCLC in preparation. A pivotal Phase 2 study of IBI363 in melanoma in China is expected to read out in the second half of 2026, potentially supporting the first NDA submission for IBI363. IBI363 has demonstrated preliminary positive PoC results in first-line NSCLC. PoC studies in first-line NSCLC and first-line colorectal cancer are ongoing, with additional PoC studies being advanced across other tumor types, further supporting its potential as a next-generation IO backbone therapy. Arcotatug Tavetecan (CLDN18.2 ADC, Innovent/Takeda R&D Code: IBI343/TAK-921): Globally First NDA stage Next-Generation Fc-Silenced CLDN18.2 ADC, potential TAM over US$8 billion The China-Japan multicenter Phase 3 study completed its first interim analysis and achieved primary endpoint. The NDA submission has been accepted by NMPA for the treatment of CLDN18.2-positive advanced gastric cancer in later-line settings. A Phase 3 study in first-line pancreatic cancer is planned to initiate in China. International multicenter Phase 1 and PoC studies in first-line pancreatic cancer and first-line gastric cancer are ongoing. IBI324 (VEGF/ANG2, Ollin R&D Code: OLN324): Potential best-in-disease retinal therapy, potential TAM US$15 billion Our partner Ollin Biosciences reported positive results from the Phase 1b JADE head-to-head study against faricimab in nAMD and DME patients in the U.S. Ollin plans to initiate global multi-regional Phase 3 studies in DME and nAMD in the second half of 2026, and through collaboration with Innovent, to conduct patient enrollment in China and South Korea. Diversified Partnerships to Accelerate Global Innovation Over the past 10 months, Innovent has entered into strategic multi-product collaborations with global multi-national pharmaceutical companies including Takeda, Lilly and Pfizer, while partnering with biotech companies such as Ollin and Spero to rapidly validate differentiated pipeline programs in selected disease areas. The aggregate deal value reaching US$34 billion, covering more than 20 pipeline programs, among which five are "Co-Co" assets. Leveraging diversified partnership models, the Company will progressively build overseas R&D and commercialization capabilities and evolve into a truly world-class biopharmaceutical company with global business operating capabilities. High-Quality Manufacturing Standards Innovent operates advanced manufacturing facilities built to international standards and our Suzhou manufacturing site has recently undergone and successfully passed a Good Manufacturing Practice (GMP) inspection conducted by the European Medicines Agency (EMA), and has obtained the corresponding GMP certificate. Total operational capacity of 140,000 liters, accounting for 20% of China's total biologic manufacturing capacity. Suzhou site houses 60,000 liters of antibody capacity and ADC commercial lines; Hangzhou site has 80,000 liters of antibody capacity, supporting global supply and CDMO services. Sustainable Development and ESG Commitment 9,000 employees worldwide, with global R&D centers in San Francisco Bay Area, Shanghai and Suzhou. Over 3,000 new cancer patients initiate Innovent therapies daily; more than 10 million patients have benefited to date. Maintained MSCI ESG AAA rating, leading China's biopharmaceutical industry. First innovative biopharma constituent of the Hang Seng Index ("blue-chip" status). Launched community health initiatives including the MV 'Weight Management Made Easy' and documentary 'Down in Weight, Up in Life' to promote science-based healthy weight management. Published patient education materials on thyroid eye disease and weight management to enhance public health awareness. Implemented multiple patient assistance programs, benefiting over 200,000 patients with drug donations valued at over RMB 4 billion. Received honors including "Healthcare Public Welfare Pioneer" and "China Public Welfare Enterprise". Created over 2,700 jobs for new graduates. Cumulative taxes and contributions exceeding RMB 9 billion. Note: Data source: Next Pharma database. About Innovent Biologics Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 20 products in the market. It has 1 asset in NMPA NDA review, 5 assets in Phase 3 or pivotal clinical trials and 14 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Lilly, Takeda, Pfizer, Roche, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action" Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit , or follow Innovent on Facebook and LinkedIn. Statement: 1) Innovent does not recommend the use of any unapproved drug (s)/indication (s). 2) Ramucirumab (Cyramza) and Selpercatinib (Retsevmo), Pirtobrutinib (Jaypirca) and abemaciclib (Verzenios) were developed by Eli Lilly and Company. Disclaimer: Innovent does not recommend any off-label usage. Forward-Looking Statements of Innovent Biologics This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions. SOURCE Innovent Biologics 21% more press release views with Request a Demo

Phase 1Clinical ResultPhase 3Drug ApprovalPhase 2

20 Aug 2026

·www.prnewswire.com

Matwings Demonstrates Closed-Loop Protein AI Through Four AI-Wet Lab Cycles and 222 Protein Variants

The GenSci148 program illustrates a shift from one-time mutation prediction to iterative protein engineering under real drug-development constraints SHANGHAI, Aug. 20, 2026 /PRNewswire/ -- Shanghai Matwings Technology Co., Ltd. ("Matwings") today announced that GenSci148 Injection, an investigational ophthalmic biologic developed by Changchun GeneScience Pharmaceutical Co., Ltd. ("GenSci"), has received clinical trial clearance in China for neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME) and retinal vein occlusion (RVO). Matwings supported the GenSci148 program through four iterative AI–wet lab cycles covering 222 protein variants. Rather than applying AI as a one-time mutation-prediction tool, the teams repeatedly used experimental results to redesign both molecules and optimization objectives. The program progressed from improving biological activity to balancing potency, stability, expression, formulation and other development-relevant properties—illustrating a shift from predicting mutations to engineering therapeutic proteins under real drug-development constraints. Four AI–Wet Lab Cycles, 222 Variants Matwings and GenSci implemented a closed-loop workflow combining AI-guided molecular design, wet-lab testing, experimental feedback and redesign. Across four iterative cycles, the teams evaluated 222 protein variants. The first two rounds assessed 92 and 30 variants, respectively, with an initial focus on biological activity. The next two rounds evaluated 50 variants each, expanding the optimization objectives to include high-concentration formulation viscosity and broader developability requirements. Experimental results from each round were incorporated into subsequent design cycles, allowing not only the molecular designs but also the optimization objectives to evolve as evidence accumulated. The campaign therefore progressed from: activity optimization → broader developability optimization → multi-objective molecular engineering Across the optimization campaign, experimentally tested variants demonstrated improvements or favorable performance across six development-relevant properties: Together, these results reflect optimization across three increasingly demanding dimensions of therapeutic protein development: biological performance, molecular developability and formulation-relevant properties. In the nonclinical retinal model evaluated during the program, the optimized molecule maintained inhibitory activity 84 days after dosing. Under the specific experimental conditions tested, it also showed greater inhibition than aflibercept and faricimab. These findings are preclinical and do not establish comparative clinical efficacy or safety. Beyond Mutation Prediction: Engineering Proteins Under Real Drug-Development Constraints Therapeutic protein engineering requires balancing biological activity with stability, expression, formulation and other development constraints. In the GenSci148 program, experimental results continuously informed subsequent AI-guided designs, enabling the optimization process to move beyond a single fixed objective. Some experimentally validated mutations were located away from the conventional target-binding interface, illustrating how AI-guided exploration can identify productive regions of sequence space beyond interface-focused design. The program also illustrates a broader progression in protein AI validation: computational benchmarking → experimental validation → repeated integration within a real drug-development workflow GenSci148 represents the third stage of this progression, with AI-guided design and experimental evidence repeatedly linked across successive engineering cycles. The Venus Protein AI Stack Matwings' Venus protein AI stack has evolved from sequence-centered modeling toward systems integrating three-dimensional structure, evolutionary information and task-specific capabilities. Importantly, the AI-guided engineering work supporting GenSci148 was conducted using Venus 1.0, while Venus has since advanced to Venus 3.0, represented by VenusREM, which integrates protein sequence, three-dimensional structure and evolutionary information for mutation-effect prediction. Rather than relying on a single model, different components are applied to different protein R&D and engineering tasks within the broader closed-loop workflow. Certain models within the broader Venus portfolio are in development or planned stages. Together, these models form a specialist AI stack that can be combined with experimental data and iterative design across different stages of protein engineering. From External Validation to Therapeutic Creation The GenSci148 collaboration provides external validation of Matwings' protein-engineering capabilities in a real therapeutic development program. In March 2026, Matwings established Shanghai Biowings Therapeutics Co., Ltd. ("Biowings Therapeutics") to apply the same closed-loop engineering approach to internally originated therapeutic programs. Matwings develops the underlying AI and protein-engineering technology engine, while Biowings Therapeutics combines these capabilities with disease biology and drug-development expertise to create and advance therapeutic candidates. "The real test of AI for science is not whether a model performs well on a benchmark, but whether it can create measurable value through repeated design–experiment cycles in an actual R&D program," said Prof. Liang Hong, Founder and Chief Scientist of Matwings. "GenSci148 marks an important step from demonstrating individual model capabilities toward building a repeatable protein-engineering system." "Matwings contributed important molecular engineering and optimization capabilities to the GenSci148 program," said Dr. Lei Jin, CEO of GenSci. "Rather than relying on one-time predictions, the teams repeatedly combined AI-guided design with experimental evidence to improve properties relevant to drug development." About Matwings Shanghai Matwings Technology Co., Ltd. is an AI-driven protein R&D company integrating specialist AI models, computational molecular design and experimental validation to support iterative protein engineering and drug development. For more information, visit . About Biowings Therapeutics Shanghai Biowings Therapeutics Co., Ltd. focuses on AI-enabled therapeutic asset creation and clinical translation. Scientific and Development Notice: GenSci148 is an investigational product. Its safety and efficacy have not been established. Preclinical findings are specific to the experimental systems and conditions evaluated and may not predict clinical outcomes. Contact: Website: E-mail: [email protected] SOURCE Shanghai Matwings Technology Co., Ltd.; Shanghai Biowings Therapeutics Co., Ltd. 21% more press release views with Request a Demo

PROTACs

18 Aug 2026

·allsci.com

Ingenia Therapeutics lists on KOSDAQ to fund vascular antibody pipeline

Massachusetts-based Ingenia Therapeutics, a clinical-stage biotech whose lead ophthalmology antibody is being developed by Merck, began trading on KOSDAQ on August 18. Offering size, price range, and gross proceeds were not disclosed in the company's announcement. The listing reflects Ingenia's strong Korean operational roots: its core TIE-body and LCIDEC (Ligand Capture and Internalization into Endothelial Cells) platforms originate from the Korea Advanced Institute of Science and Technology (KAIST) and the Institute for Basic Science (IBS), and the company maintains a local subsidiary in Seoul, Korea, alongside its Massachusetts headquarters and Australian operations. Prior private financing rounds, named investors, and crossover participation were not disclosed. The company stated it will use IPO proceeds to advance IGT-303, a TIE2-targeting antibody for chronic kidney disease (CKD) and diabetic kidney disease, through Phase IIa trials in Australia, New Zealand, and South Korea; to advance IGT-532, an oncology candidate targeting solid tumors, toward clinical trials; and to progress preclinical assets including IGT-302 for glaucoma and IGT-627 for pulmonary arterial hypertension. Ingenia's IGT-427 was licensed to EyeBio in 2022 and is now designated MK-8748 (Tiespectus) following Merck's acquisition of EyeBio in 2024. The bispecific antibody directly agonizes the TIE2 receptor while inhibiting VEGF, and Merck is advancing it into Phase III development across wet age-related macular degeneration and diabetic macular edema. Ingenia retains no development responsibility for MK-8748; milestone, royalty, or other payment terms under the licensing agreement were not disclosed. The company's second clinical asset, IGT-303, completed first-in-human dosing in November 2025 and is progressing through a Phase I/IIa trial, with data expected in the second half of 2026. No regulatory designations were disclosed for either clinical asset. In the TIE2-targeted retinal space, Merck's development of MK-8748 positions it against established anti-VEGF agents including aflibercept and ranibizumab, as well as faricimab, Roche's approved bispecific antibody targeting both Ang-2 and VEGF-A, which acts on the same vascular stabilization pathway through a distinct mechanism. Spot something wrong? Report an issue with this article

License out/inPhase 1Drug ApprovalAcquisitionPhase 2

100 Deals associated with Faricimab

External Link

KEGG	Wiki	ATC	Drug Bank
D11516	Faricimab	-	DB15303

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Angioid Streaks	Japan	Chugai Pharmaceutical Co., Ltd.	19 May 2025
Retinal vein occlusion-related macular edema	Australia	Roche Products Pty Ltd.	08 Aug 2022
Age Related Macular Degeneration	Japan	Chugai Pharmaceutical Co., Ltd.	28 Mar 2022
Choroidal Neovascularization	Japan	Chugai Pharmaceutical Co., Ltd.	28 Mar 2022
Dystrophy, Macular	Japan	Chugai Pharmaceutical Co., Ltd.	28 Mar 2022
Diabetic macular oedema	United States	Genentech, Inc.	28 Jan 2022
Wet age-related macular degeneration	United States	Genentech, Inc.	28 Jan 2022

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Retinal Vein Occlusion	NDA/BLA	United States	Roche Holding AG	09 May 2023
Proliferative retinopathy with diabetes mellitus	Phase 3	United States	Genentech, Inc.	04 Aug 2025
Myopic choroidal neovascularization	Phase 3	China	F. Hoffmann-La Roche Ltd.	28 Feb 2024
Myopic choroidal neovascularization	Phase 3	China	Roche China Holding Ltd.	28 Feb 2024
Myopic choroidal neovascularization	Phase 3	Australia	F. Hoffmann-La Roche Ltd.	28 Feb 2024
Myopic choroidal neovascularization	Phase 3	Australia	Roche China Holding Ltd.	28 Feb 2024
Myopic choroidal neovascularization	Phase 3	France	Roche China Holding Ltd.	28 Feb 2024
Myopic choroidal neovascularization	Phase 3	France	F. Hoffmann-La Roche Ltd.	28 Feb 2024
Myopic choroidal neovascularization	Phase 3	Germany	F. Hoffmann-La Roche Ltd.	28 Feb 2024
Myopic choroidal neovascularization	Phase 3	Germany	Roche China Holding Ltd.	28 Feb 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ALTIMETER (Pubmed \| Ophthalmol Sci)	Phase 2	Diabetic macular oedema	99	Faricimab 6.0 mg	sqnbzjpakc(vjnopzkumb) = bsfkeharlp zuruatsfnv (hhnflguzcv, 7.5 - 10.9) View more	Positive	01 May 2026
NCT03823287 \| NCT03823300 (TENAYA, Pubmed \| Ophthalmol Sci)	Phase 3	Wet age-related macular degeneration	1,329	Faricimab 6 mg	gsxqvkxzwn(uxftkzuaji) = iojcdnxqgn wqrxkhxgad (imxagatjuu ) View more	Positive	01 May 2026
NCT03823287 \| NCT03823300 (TENAYA, Pubmed \| Ophthalmol Sci)	Phase 3	Wet age-related macular degeneration	1,329	Aflibercept 2 mg	gsxqvkxzwn(uxftkzuaji) = wbkgrhliuq wqrxkhxgad (imxagatjuu ) View more	Positive	01 May 2026
NCT03622593 (RHINE, Pubmed \| Ophthalmol Ther)	Phase 3	Diabetic macular oedema	152	Faricimab 6.0 mg every 8 weeks (Q8W)	pftefnplzl(lfbsytuyxx) = hohllmbugd hngyhmhplb (phtkgbubsh )	Positive	10 Apr 2026
NCT03622593 (RHINE, Pubmed \| Ophthalmol Ther)	Phase 3	Diabetic macular oedema	152	Faricimab 6.0 mg treat-and-extend (T&E)	pftefnplzl(lfbsytuyxx) = vxmyxwkffp hngyhmhplb (phtkgbubsh )	Positive	10 Apr 2026
APAO2026	Not Applicable	-	159	Aflibercept 8 mg	-	Positive	18 Feb 2026
APAO2026	Not Applicable	-	159	Faricimab	iiuxsahylg(veacalnjoi) = joepgsgsfn huzateobmg (cjrnurietf )	Positive	18 Feb 2026
APAO2026	Not Applicable	Retinal Diseases	80	Faricimab	syhiitmkbj(dhquqgaqxt) = jyjcvzlxgz fskbmrzbpc (vmvfuhfyli ) View more	Positive	18 Feb 2026
APAO2026	Not Applicable	Retinal Vein Occlusion	18	Faricimab	hbjaampxqf(tzbvbbhyjg) = mwftbmmjbp ayidkjczas (bppcdolxru, 40 - 81) View more	Positive	18 Feb 2026
APAO2026	Not Applicable	Wet age-related macular degeneration	50	Faricimab 6 mg/0.05 ml (refractory nAMD)	eznytnowxx(iqwqulavjv) = ddiuovvuqs apwgxzkjsb (hayqnkofds, 0.55) View more	Positive	18 Feb 2026
APAO2026	Not Applicable	Diabetic macular oedema \| Retinal Vein Occlusion	128	Faricimab	mavisyzutr(ygqswnjyqg) = no significant ocular or systemic adverse events were observed in all groups. jgezmdaflf (cyftdqtrqc ) View more	Positive	18 Feb 2026
APAO2026	Not Applicable	Diabetic macular oedema \| Retinal Vein Occlusion	128	Ranibizumab		Positive	18 Feb 2026
APAO2026	Not Applicable	Diabetic macular oedema	11	Faricimab (Diabetic Macular Edema)	arcxhafkha(toecmzbvzy) = vkgfroteup xobuhzadlp (kzxvbldiky ) View more	Positive	18 Feb 2026
APAO2026	Not Applicable	Wet age-related macular degeneration	57	Faricimab	nkyrcvwiyw(ivzalnfeun) = gzlooqxkck ikwuoreogm (xzxqqmgspt ) View more	Positive	18 Feb 2026

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis